| Thoracic radiotherapy plus maintenance durvalumab after first line carboplatin and etoposide plus durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) - A multicenter single arm open label phase II trial (SAKK 15/19) | European journal of cancer | | | 2026 | 14 | 91 |
|
| Sarcomes des tissus mous : une approche nécessairement multidisciplinaire | Revue médicale suisse | | | 2025 | 20 | 0 |
|
| Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer | The New England journal of medicine | | | 2025 | 107 | 0 |
|
| Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy : results of SAKK 11/16, a phase IIa trial | Experimental hematology & oncology | | | 2025 | 71 | 112 |
|
| Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcomas : Looking Forward to What Is Next | Journal of clinical oncology | | | 2024 | 25 | 270 |
|
| A First-in-Human Phase I Clinical Study with MVX-ONCO-1, a Personalized Active Immunotherapy, in Patients with Advanced Solid Tumors | Cancer research communications | | | 2024 | 119 | 246 |
|
| Sabatolimab in combination with spartalizumab in patients with non-small cell lung cancer or melanoma who received prior treatment with anti-PD-1/PD-L1 therapy : a phase 2 multicentre study | BMJ open | | | 2024 | 80 | 109 |
|
| Effectiveness of fractionated rituximab in preventing tumor lysis syndrome in aggressive B-cell lymphoma : Insights from real-life clinical practice | Cancer reports | | | 2024 | 77 | 654 |
|
| ONE SHOT - single shot radiotherapy for localized prostate cancer : 18-month results of a single arm, multicenter phase I/II trial | Radiotherapy and oncology | | | 2024 | 100 | 84 |
|
| LBA46 SAKK 11/16, a phase IIa trial evaluating overall survival (OS) for recurrent/metastatic Head & neck squamous cell carcinoma (RMHNSCC) patients (pts) progressing after ≥ 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy | ESMO Congress 2023 | | | 2023 | 132 | 183 |
|
| Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins | iScience | | | 2023 | 110 | 79 |
|
| Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity | BMJ open | | | 2023 | 506 | 120 |
|
| PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : Acute Toxicity of a Randomized Phase 2 Trial | European urology oncology | | | 2023 | 91 | 0 |
|
| The Future of Cancer Immunotherapy | Praxis | | | 2023 | 118 | 2 |
|
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence | Oral oncology | | | 2023 | 112 | 1,154 |
|
| Sustained delivery of low-dose anti-CTLA-4 by genetically engineered encapsulated cells to the tumor microenvironment drives tumor response and prolongs survival in a colorectal cancer model | AACR Annual Meeting 2023 | | | 2023 | 86 | 248 |
|
| Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17 | Journal of clinical oncology | | | 2023 | 110 | 316 |
|
| Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13) | EClinicalMedicine | | | 2023 | 92 | 166 |
|
| SARS-CoV-2 m-RNA Vaccine Response in Immunocompromised Patients: A Monocentric Study Comparing Cancer, People Living with HIV, Hematopoietic Stem Cell Transplant Patients and Lung Transplant Recipients | Vaccines | | | 2023 | 101 | 170 |
|
| Personalized immunotherapy with encapsulated cell technology : Feasibility, safety and efficacy results from the first-in-human clinical trial in advanced relapsing solid tumors | ESMO Congress 2022 | | | 2022 | 100 | 210 |
|
| Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA) | Cancers | | | 2022 | 141 | 380 |
|
| Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study | Lung cancer | | | 2022 | 235 | 315 |
|
| 1454P Optimizing ipilimumab in RCC : Results from SAKK 07/17 (CM-980) nivolumab (N) + ipilimumab (Ipi) in mRCC | ESMO Congress 2022 | | | 2022 | 94 | 80 |
|
| Humoral and cellular immunogenicity two months after SARS-CoV-2 messenger RNA vaccines in patients with cancer | iScience | | | 2022 | 250 | 211 |
|
| SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma | Blood advances | | | 2022 | 157 | 669 |
|
| LBA65 SAKK 08/14 - IMPROVE Investigation of metformin in patients with metastatic castration-resistant prostate cancer (mCRPC) in combination with enzalutamide vs. enzalutamide alone. A randomized, open label, phase II trial | ESMO Congress 2022 | | | 2022 | 100 | 104 |
|
| 658MO Pembrolizumab (pembro) vs standard-of-care (SOC) in previously treated recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 6-year follow-up of KEYNOTE-040 | European Society for Medical Oncology (ESMO) Congress | | | 2022 | 90 | 0 |
|
| Immortalised human myoblast cell lines for the delivery of therapeutic proteins using encapsulated cell technology | Molecular therapy. Methods & clinical development | | | 2022 | 257 | 189 |
|
| Local sustained GM-CSF delivery by genetically engineered encapsulated cells enhanced both cellular and humoral SARS-CoV-2 spike-specific immune response in an experimental murine spike DNA vaccination model | Vaccines | | | 2021 | 245 | 303 |
|
| A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein | Vaccines | | | 2021 | 340 | 234 |
|
| SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial | Journal of Clinical Oncology | | | 2021 | 274 | 0 |
|
| Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors | Clinical Cancer Research | | | 2021 | 613 | 1 |
|
| Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer | Cancer Cell | | | 2021 | 305 | 455 |
|
| Primary extra-osseous ewing sarcoma of the thyroid: a case report and review of the literature | Head and Neck Pathology | | | 2021 | 278 | 387 |
|
| Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040 | Journal of the National Cancer Institute | | | 2021 | 223 | 0 |
|
| Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study | Clinical Cancer Research | | | 2020 | 189 | 0 |
|
| Swiss experience of atezolizumab for platinum-pretreated urinary tract carcinoma: the SAUL study in real-world practice | Schweizerische medizinische Wochenschrift | | | 2020 | 203 | 97 |
|
| Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study | The Lancet | | | 2019 | 235 | 0 |
|
| Preoperative chemotherapy and radiotherapy concomitant to cetuximab in resectable stage IIIB NSCLC: a multicentre phase 2 trial (SAKK 16/08) | British Journal of Cancer | | | 2019 | 224 | 105 |
|
| Multimodal Treatment in Operable Stage III NSCLC: A Pooled Analysis on Long-Term Results of Three SAKK trials (SAKK 16/96, 16/00, and 16/01) | Journal of Thoracic Oncology | | | 2019 | 199 | 166 |
|
| Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy | Blood | | | 2019 | 92 | 277 |
|
| Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma | Blood | | | 2018 | 166 | 0 |
|
| Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial | Oral oncology | | | 2018 | 83 | 0 |
|
| First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies | OncoImmunology | | | 2017 | 667 | 9 |
|
| Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial | Clinical lung cancer | | | 2017 | 559 | 1 |
|
| A drug–drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors | Cancer chemotherapy and pharmacology | | | 2017 | 86 | 0 |
|
| Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers | Cancer immunology research | | | 2016 | 79 | 0 |
|
| 143PD: Bevacizumab and pemetrexed versus pemetrexed alone as maintenance therapy for patients with advanced nonsquamous NSCLC: Results of the expanded SAKK19/09 trial | Journal of thoracic oncology | | | 2016 | 531 | 184 |
|
| Giant Cell Tumor of Bone With Pseudosarcomatous Changes Leading to Premature Denosumab Therapy Interruption: A Case Report With Review of the Literature | International journal of surgical pathology | | | 2016 | 567 | 0 |
|
| Rituximab, bendamustine and lenalidomide in patients with aggressive B‐cell lymphoma not eligible for anthracycline‐based therapy or intensive salvage chemotherapy – SAKK 38/08 | British journal of haematology | | | 2016 | 103 | 0 |
|
| Comparison of the incidence of osteoradionecrosis with conventional radiotherapy and intensity-modulated radiotherapy | Head & neck | | | 2016 | 664 | 1 |
|
| Encapsulated cellular implants for recombinant protein delivery and therapeutic modulation of the immune system | International journal of molecular sciences | | | 2015 | 220 | 220 |
|
| Traitement des carcinomes épidermoïdes ORL chez la personne âgée | Revue médicale suisse | | | 2015 | 494 | 0 |
|
| Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation : Phase II Trial SAKK19/09 | Clinical lung cancer | | | 2015 | 79 | 0 |
|
| Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma | British journal of cancer | | | 2014 | 679 | 248 |
|
| Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial | Lancet oncology | | | 2014 | 211 | 0 |
|
| Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors | Cancer immunology and immunotherapy | | | 2014 | 149 | 0 |
|
| Chirurgie du cancer pulmonaire à petites cellules de stade précoce: doit-on réévaluer son rôle? | Revue médicale suisse | | | 2013 | 174 | 211 |
|
| Cancers liés au HPV: faut-il vacciner les jeunes hommes? | Revue médicale suisse | | | 2012 | 228 | 115 |
|
| Role of the cytokine GM-CSF in cell-based anti-tumor immunity: learning from murine models to engineer new therapeutic strategies | | | | 2012 | 771 | 990 |
|
| Le cancer du poumon chez la femme est-il différent? | Revue médicale suisse | | | 2012 | 172 | 275 |
|
| Thérapies ciblées du cancer pulmonaire: tests moléculaires à partir d'échantillons cytologiques | Revue médicale suisse | | | 2011 | 637 | 3 |
|
| Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy | Cancer gene therapy | | | 2011 | 915 | 0 |
|
| Anticancéreux sous haute tension | Revue médicale suisse | | | 2011 | 577 | 1 |
|
| Role of GM-CSF signaling in cell-based tumor immunization | Blood | | | 2009 | 885 | 133 |
|
| Is there a place for low-dose chest and prophylactic brain irradiation in limited-disease small cell lung cancer | Medical oncology | | | 2009 | 659 | 0 |
|
| Intravenous leiomyomatosis of the uterus: link with new fertilisation methods? | Schweizerische medizinische Wochenschrift | | | 2009 | 626 | 414 |
|
| Intestinal colonization of IL-2 deficient mice with non-colitogenic B. vulgatus prevents DC maturation and T-Cell polarization | PloS one | | | 2008 | 139 | 121 |
|
| Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03 | Annals of oncology | | | 2008 | 210 | 142 |
|
| CCR9 is a homing receptor for plasmacytoid dendritic cells to the small intestine | Proceedings of the National Academy of Sciences of the United States of America | | | 2007 | 152 | 0 |
|
| Phase I trial of concomitant hyperfractionated radiotherapy with docetaxel and cisplatin for locally advanced head and neck cancer | The cancer journal | | | 2006 | 705 | 595 |
|
| Use of a prospective risk analysis method to improve the safety of the cancer chemotherapy process | International journal for quality in health care | | | 2006 | 133 | 0 |
|
| Can concomitant-boost accelerated radiotherapy be adopted as routine treatment for head-and-neck cancers? A 10-year single-institution experience | International journal of radiation oncology, biology, physics | | | 2004 | 621 | 715 |
|
| Quality of life in patients with oropharynx carcinomas: assessment after accelerated radiotherapy with or without chemotherapy versus radical surgery and postoperative radiotherapy | Head & neck | | | 2003 | 691 | 1,413 |
|
| CD1d-restricted T cells regulate dendritic cell function and antitumor immunity in a granulocyte-macrophage colony-stimulating factor-dependent fashion | Proceedings of the National Academy of Sciences of the United States of America | | | 2003 | 95 | 50 |
|
| In vivo evidence for the role of GM-CSF as a mediator in acute pancreatitis-associated lung injury | American journal of physiology. Lung cellular and molecular physiology | | | 2002 | 96 | 0 |
|
| Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation | Cancer research | | | 2001 | 109 | 0 |
|
| Overlapping roles for granulocyte-macrophage colony-stimulating factor and interleukin-3 in eosinophil homeostasis and contact hypersensitivity | Blood | | | 2001 | 82 | 137 |
|
| Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand | Cancer research | | | 2000 | 97 | 0 |
|
| Cytokine-secreting tumor cell vaccines | Current opinion in immunology | | | 2000 | 81 | 0 |
|
| Role for interleukin-3 in mast-cell and basophil development and in immunity to parasites | Nature | | | 1998 | 109 | 0 |
|
| Involvement of interleukin-3 in delayed-type hypersensitivity | Blood | | | 1998 | 68 | 102 |
|
| Fatal infection with a novel, unidentified mycobacterium in a man with the acquired immunodeficiency syndrome | The New England journal of medicine | | | 1990 | 670 | 210 |
|
